321 related articles for article (PubMed ID: 30228937)
21. Downregulation of CD73 associates with T cell exhaustion in AML patients.
Kong Y; Jia B; Zhao C; Claxton DF; Sharma A; Annageldiyev C; Fotos JS; Zeng H; Paulson RF; Prabhu KS; Zheng H
J Hematol Oncol; 2019 Apr; 12(1):40. PubMed ID: 31014364
[TBL] [Abstract][Full Text] [Related]
22. IFN-γ decreased the suppressive function of CD33
Zhan X; Hu S; Wu Y; Li M; Liu T; Ming S; Wu M; Liu M; Huang X
Mol Immunol; 2018 Feb; 94():107-120. PubMed ID: 29291452
[TBL] [Abstract][Full Text] [Related]
23. Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors-Comparison Against a Therapy Naïve Cohort.
Schoop H; Bregenzer A; Halske C; Behrens HM; Krüger S; Egberts JH; Röcken C
Transl Oncol; 2020 Feb; 13(2):165-176. PubMed ID: 31865179
[TBL] [Abstract][Full Text] [Related]
24. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
25. Defining the Signature of VISTA on Myeloid Cell Chemokine Responsiveness.
Broughton TWK; ElTanbouly MA; Schaafsma E; Deng J; Sarde A; Croteau W; Li J; Nowak EC; Mabaera R; Smits NC; Kuta A; Noelle RJ; Lines JL
Front Immunol; 2019; 10():2641. PubMed ID: 31803182
[TBL] [Abstract][Full Text] [Related]
26. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
27. Scrutinizing the Expression and Blockade of Inhibitory Molecules Expressed on T Cells from Acute Myeloid Leukemia Patients.
Abdolmaleki M; Mojtabavi N; Zavvar M; Vaezi M; Noorbakhsh F; Nicknam MH
Iran J Allergy Asthma Immunol; 2018 Jun; 17(3):265-273. PubMed ID: 29908544
[TBL] [Abstract][Full Text] [Related]
28. Ligand-Receptor Interactions of Galectin-9 and VISTA Suppress Human T Lymphocyte Cytotoxic Activity.
Yasinska IM; Meyer NH; Schlichtner S; Hussain R; Siligardi G; Casely-Hayford M; Fiedler W; Wellbrock J; Desmet C; Calzolai L; Varani L; Berger SM; Raap U; Gibbs BF; Fasler-Kan E; Sumbayev VV
Front Immunol; 2020; 11():580557. PubMed ID: 33329552
[TBL] [Abstract][Full Text] [Related]
29. Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma.
Wu L; Deng WW; Huang CF; Bu LL; Yu GT; Mao L; Zhang WF; Liu B; Sun ZJ
Cancer Immunol Immunother; 2017 May; 66(5):627-636. PubMed ID: 28236118
[TBL] [Abstract][Full Text] [Related]
30. Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia.
Sun H; Li Y; Zhang ZF; Ju Y; Li L; Zhang BC; Liu B
Int J Hematol; 2015 Nov; 102(5):579-86. PubMed ID: 26358057
[TBL] [Abstract][Full Text] [Related]
31. Tim-3 is highly expressed in T cells in acute myeloid leukemia and associated with clinicopathological prognostic stratification.
Li C; Chen X; Yu X; Zhu Y; Ma C; Xia R; Ma J; Gu C; Ye L; Wu D
Int J Clin Exp Pathol; 2014; 7(10):6880-8. PubMed ID: 25400771
[TBL] [Abstract][Full Text] [Related]
32. V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma.
Mutsaers P; Balcioglu HE; Kuiper R; Hammerl D; Wijers R; van Duin M; van der Holt B; Broijl A; Gregory W; Zweegman S; Sonneveld P; Debets R
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34066382
[TBL] [Abstract][Full Text] [Related]
33. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights.
Noelle RJ; Lines JL; Lewis LD; Martell RE; Guillaudeux T; Lee SW; Mahoney KM; Vesely MD; Boyd-Kirkup J; Nambiar DK; Scott AM
Front Oncol; 2023; 13():1225081. PubMed ID: 37795437
[TBL] [Abstract][Full Text] [Related]
34. Myeloid-Derived Suppressor Cells Associated With Disease Progression in Primary HIV Infection: PD-L1 Blockade Attenuates Inhibition.
Zhang ZN; Yi N; Zhang TW; Zhang LL; Wu X; Liu M; Fu YJ; He SJ; Jiang YJ; Ding HB; Chu ZX; Shang H
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):200-208. PubMed ID: 28570288
[TBL] [Abstract][Full Text] [Related]
35. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
[TBL] [Abstract][Full Text] [Related]
36. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer.
Digomann D; Strack J; Heiduk M; Plesca I; Rupp L; Reiche C; Nicolaus S; Beer C; Sommer U; Schmitz M; Distler M; Weitz J; Seifert AM; Seifert L
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190254
[TBL] [Abstract][Full Text] [Related]
37. PD-1 blockade potentially enhances adoptive cytotoxic T cell potency in a human acute myeloid leukaemia animal model.
Deng R; Fan FY; Yi H; Liu F; He GC; Sun HP; Su Y
Hematology; 2018 Dec; 23(10):740-746. PubMed ID: 29962321
[TBL] [Abstract][Full Text] [Related]
38. VISTA inhibitors in cancer immunotherapy: a short perspective on recent progresses.
Wu C; Cao X; Zhang X
RSC Med Chem; 2021 Oct; 12(10):1672-1679. PubMed ID: 34778768
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA.
Pan J; Chen Y; Zhang Q; Khatun A; Palen K; Xin G; Wang L; Yang C; Johnson BD; Myers CR; Sei S; Shoemaker RH; Lubet RA; Wang Y; Cui W; You M
Commun Biol; 2021 Jul; 4(1):906. PubMed ID: 34302042
[TBL] [Abstract][Full Text] [Related]
40. Vδ2 T cell subsets, defined by PD-1 and TIM-3 expression, present varied cytokine responses in acute myeloid leukemia patients.
Wu K; Feng J; Xiu Y; Li Z; Lin Z; Zhao H; Zeng H; Xia W; Yu L; Xu B
Int Immunopharmacol; 2020 Mar; 80():106122. PubMed ID: 31955066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
